Prakt. lékáren. 2014; 10(5): 174-176

Pharmacological management of pituitary adenomas

Filip Gabalec, Jan Čáp
IV. interní hematologická klinika, Fakultní nemocnice Hradec Králové a Univerzita Karlova v Praze,
Lékařská fakulta v Hradci Králové

Neurosurgery, radiation and pharmacological approach are the treatment modalities for pituitary adenomas. Dopamine agonists are

the treatment of choice in prolactinomas. Neurosurgery is the first choice for acromegaly, Cushing´s syndrome and TSH adenomas.

Dopamine and somatostatin analogues are mostly used before operation, when surgery fails, until effect of radiation therapy and to

reduce symptoms of disease. A blocator of growth hormone is also used in acromegaly. The blocators of steroidogenesis in adrenals are

also used in ACTH producing adenomas.

Keywords: prolactinoma, acromegaly, Cushing´s syndrome, pituitary adenoma, dopamine analogues, somatostatin analogues

Published: October 24, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gabalec F, Čáp J. Pharmacological management of pituitary adenomas. Praktické lékárenství. 2014;10(5):174-176.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML & McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer 2004; 101: 613-619. Go to original source... Go to PubMed...
    2. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 2006; 91: 4769-4775. Go to original source... Go to PubMed...
    3. Marek J. Hormonální substituční terapie z pohledu endokrinologa. Prakt. lékáren 2010; 5: 222-226.
    4. Lamberts SW & Macleod RM. Regulation of prolactin secretion at the level of the lactotroph. Physiol Rev 1990; 70: 279-318. Go to original source... Go to PubMed...
    5. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C & Beckers A. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84: 2518-2522. Go to original source... Go to PubMed...
    6. Colao A & Savastano S. Medical treatment of prolactinomas. Nat Rev Endocrinol 2011; 7: 267-278. Go to original source... Go to PubMed...
    7. Hána V, Švancara J, Bandúrová L, Brabec P, Čáp J, Ďurovcová V, Dvořáková E, Hána Vj, Jarkovská Z, Kentoš P, Klimeš D, Krčma M, Kršek M, Lazurova I, Olšovská V, Podoba J, Pura M, Sasiková M, Starý K, Strenková J, Šiprová H, Štěňo J, Trejbalová L, Vaňuga P, Wagnerová H, weiss V, Zeman D, Dušek L & Marek J. Registry of sellar tumors - RESET: Diagnostics and therapy of acromegaly in Czech and Slovak republics in the 21st century. Diabetes, Metabolismus, Endokrinologie a Výživa 2013; 16: 219-224.
    8. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I & Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One 2012; 7: e36411. Go to original source... Go to PubMed...
    9. Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Resendiz K, Ruffin M, Chen Y, Sheppard M & Pasireotide CSG. Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study. J Clin Endocrinol Metab 2014; 99: 791-799. Go to original source... Go to PubMed...
    10. Hodish I & Barkan A. Long-term effects of pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 2008; 4: 324-332. Go to original source... Go to PubMed...
    11. van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM & Koltowska-Haggstrom M. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 2012; 97: 1589-1597. Go to original source... Go to PubMed...
    12. Neggers SJ, Franck SE, de Rooij FW, Dallenga AH, Poublon RM, Feelders RA, Janssen JA, Buchfelder M, Hofland LJ, Jorgensen JO & van der Lely AJ. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogues in acromegaly. J Clin Endocrinol Metab 2014; jc20142032. Go to original source... Go to PubMed...
    13. Dekkers OM, Pereira AM & Romijn JA. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab 2008; 93: 3717-3726. Go to original source... Go to PubMed...
    14. Kršek M, Čáp J, Hána V & Marek J. Doporučení České endokrinologické společnosti pro léčbu Cushingova syndromu v dospělosti. Vnitr Lek 2013; 59: 819-827. Go to PubMed...
    15. Masopust V, Netuka D, Hána V, Marek J & Beneš V. Surgical treatment of hormonally active hypophysial adenoma. Cesk Slov Neurol N 2007; 4: 402-406.
    16. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM & Pasireotide BSG. A 12-month phase 3 study of pasireotide in Cushing's disease. N Engl J Med 2012; 366: 914-924. Go to original source... Go to PubMed...
    17. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ & Lamberts SW. Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 2010; 362: 1846-1848. Go to original source... Go to PubMed...
    18. Breitschaft A, Hu K, Hermosillo Resendiz K, Darstein C & Golor G. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 2014; 103: 458-465. Go to original source... Go to PubMed...
    19. Beck-Peccoz P & Persani L. Medical management of thyrotropin-secreting pituitary adenomas. Pituitary 2002; 5: 83-88. Go to original source... Go to PubMed...
    20. Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J & Brue T. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 2012; 76: 769-775. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.